Immunodeficiency 45

Summary

Immunodeficiency 45 (MONDO:0014727) is a disease caused by IFNAR2 (GenCC Strong), with 1 cohort gene.

At a glance

• Causal gene: IFNAR2 (GenCC Strong)
• Cohort genes: 1
• ClinVar variants: 14

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	immunodeficiency 45
Mondo ID	MONDO:0014727
OMIM	616669
DOID	DOID:0111994
UMLS	C4225252
MedGen	901044
Is cancer (heuristic)	no

Also known as: IMD45 · immunodeficiency 45 · immunodeficiency type 45

Data availability: 14 ClinVar variants · 3 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › immunodeficiency disease › immunodeficiency 45

Related subtypes (94): B cell deficiency, T-cell immunodeficiency, complement deficiency, myalgic encephalomeyelitis/chronic fatigue syndrome, hypoproteinemia, hypercatabolic, X-linked lymphoproliferative syndrome, Wiskott-Aldrich syndrome, autosomal dominant form, immunodeficiency due to CD25 deficiency, immunodeficiency 67, primary immunodeficiency with natural-killer cell deficiency and adrenal insufficiency, immunodeficiency 35, pyogenic bacterial infections due to MyD88 deficiency, lymphoproliferative syndrome 1, FADD-related immunodeficiency, immunodeficiency 31B, Wiskott-Aldrich syndrome 2, cryptosporidiosis-chronic cholangitis-liver disease syndrome, idiopathic CD4 lymphocytopenia, immunodeficiency 23, DOCK2 deficiency, TFRC-related combined immunodeficiency, combined immunodeficiency, autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome, immunodeficiency due to selective anti-polysaccharide antibody deficiency, immunodeficiency 57, immunodeficiency 14b, autosomal recessive, immunodeficiency 98 with autoinflammation, X-linked, immunodeficiency 102, immunodeficiency 74, COVID-19-related, X-linked, immunodeficiency 66, immunodeficiency 80 with or without congenital cardiomyopathy, immunodeficiency 81, immunodeficiency 82 with systemic inflammation, immunodeficiency 84, immunodeficiency 85 and autoimmunity, immunodeficiency 86, immunodeficiency 87 and autoimmunity, immunodeficiency 88, immunodeficiency 89 and autoimmunity, immunodeficiency 91 and hyperinflammation, immunodeficiency 92, immunodeficiency 93 and hypertrophic cardiomyopathy, immunodeficiency 95, immunodeficiency 96, immunodeficiency 97 with autoinflammation, immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias, immunodeficiency 101 (varicella zoster virus-specific), immunodeficiency 75, immunodeficiency 76, immunodeficiency 106, susceptibility to viral infections, immunodeficiency 78 with autoimmunity and developmental delay, immunodeficiency 77, immunodeficiency 107, susceptibility to invasive staphylococcus aureus infection, immunodeficiency 15a, immunodeficiency 60, immunodeficiency 62, immunodeficiency 63 with lymphoproliferation and autoimmunity, immunodeficiency 64, immunodeficiency 65, susceptibility to viral infections, immunodeficiency 69, immunodeficiency 70, immunodeficiency 72 with autoinflammation, GATA2 deficiency with susceptibility to MDS/AML, Shwachman-Diamond syndrome 1, immunodeficiency 53, immunodeficiency 11b with atopic dermatitis, IKBKG-related immunodeficiency with or without ectodermal dysplasia, FNIP1-associated syndrome, FASLG-related immunodeficiency, TNFRSF9-related immunodeficiency, DNAJC21-related Shwachman Diamond syndrome, IRF4-related immune disorder, PTEN harmartoma tumor syndrome with immune disorder, primary immunodeficiency due to calcium channel deficiency, chronic mucocutaneous candidiasis and connective tissue disease due to JNK1 haploinsufficiency, immune deficiency due to impaired neutrophil phagocytosis and migration, hatipoglu immunodeficiency syndrome, immunodeficiency 112, immunodeficiency 113 with autoimmunity and autoinflammation, immunodeficiency 114, folate-responsive, immunodeficiency 115 with autoinflammation, immunodeficiency 117, immunodeficiency 118, immunodeficiency 119, immunodeficiency 121 with autoinflammation, immunodeficiency 122, immunodeficiency 123 with HPV-related verrucosis, immunodeficiency 125, immunodeficiency 126, susceptibility to, immunodeficiency 127, immunodeficiency 128, immunodeficiency 132b, immunodeficiency 133 with ectodermal dysplasia with or without peripheral neuropathy, immunodeficiency 134 (Epstein-Barr virus-specific)

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

14 retrieved; paginated sample, class counts are floors:

4 benign, 3 uncertain significance, 3 conflicting classifications of pathogenicity, 2 pathogenic, 1 likely pathogenic, 1 pathogenic/likely pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
218160	NM_001289125.3(IFNAR2):c.311del (p.Glu104fs)	IFNAR2	Pathogenic	criteria provided, single submitter
976791	NM_207585.3(IFNAR2):c.555_559del (p.Ile185fs)	IFNAR2	Pathogenic	criteria provided, multiple submitters, no conflicts
977219	NM_207585.3(IFNAR2):c.236del (p.Asp78_Leu79insTer)	IFNAR2	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts
3068469	NM_001289125.3(IFNAR2):c.158_160del (p.Ser53del)	IFNAR2	Likely pathogenic	criteria provided, single submitter
1521930	NM_001289125.3(IFNAR2):c.343G>A (p.Gly115Arg)	IFNAR2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1673082	NM_001289125.3(IFNAR2):c.505G>A (p.Val169Ile)	IFNAR2	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
994273	NM_001289125.3(IFNAR2):c.157T>C (p.Ser53Pro)	IFNAR2-IL10RB	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications
1004056	NM_001289125.3(IFNAR2):c.1067A>G (p.Glu356Gly)	IFNAR2	Uncertain significance	criteria provided, multiple submitters, no conflicts
1029538	NM_001289125.3(IFNAR2):c.841-102G>A	IFNAR2	Uncertain significance	criteria provided, single submitter
1435309	NM_001289125.3(IFNAR2):c.840+1G>T	IFNAR2	Uncertain significance	criteria provided, multiple submitters, no conflicts
1170800	NM_001289125.3(IFNAR2):c.28T>G (p.Phe10Val)	IFNAR2	Benign	criteria provided, multiple submitters, no conflicts
1684583	NM_001289125.3(IFNAR2):c.541-50A>G	IFNAR2	Benign	criteria provided, multiple submitters, no conflicts
7288	NM_001289125.3(IFNAR2):c.23T>C (p.Phe8Ser)	IFNAR2	Benign	criteria provided, multiple submitters, no conflicts
1285251	NM_001289125.3(IFNAR2):c.841-4del	IFNAR2-IL10RB	Benign	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 3 · Orphanet: 1 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
IFNAR2	Strong	Autosomal recessive	immunodeficiency 45	3

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
IFNAR2	Orphanet:431166	Primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
IFNAR2	HGNC:5433	ENSG00000159110	P48551	Interferon alpha/beta receptor 2	gencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
IFNAR2	Interferon alpha/beta receptor 2	Together with IFNAR1, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa).

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Antibody/Immunoglobulin	1	29.2×	0.034

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
IFNAR2	Antibody/Immunoglobulin	yes		FN3_dom, Ig-like_fold, Interferon/interleukin_rcp_dom

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	1
unknown	0

Top tissues across cohort

Tissue	Cohort genes
blood	1
leukocyte	1
monocyte	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
IFNAR2	275	ubiquitous	marker	blood, monocyte, leukocyte

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
IFNAR2	2,159

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
IFNAR2	P48551	9

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 5. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Regulation of IFNA/IFNB signaling	1	439.2×	0.008	IFNAR2
Evasion by RSV of host interferon responses	1	326.3×	0.008	IFNAR2
Interferon alpha/beta signaling	1	152.3×	0.011	IFNAR2
Potential therapeutics for SARS	1	114.2×	0.011	IFNAR2
SARS-CoV-2 activates/modulates innate and adaptive immune responses	1	89.2×	0.011	IFNAR2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
response to interferon-alpha	1	1685.2×	0.003	IFNAR2
response to interferon-beta	1	1532.0×	0.003	IFNAR2
cellular response to interferon-beta	1	526.6×	0.006	IFNAR2
type I interferon-mediated signaling pathway	1	343.9×	0.006	IFNAR2
cell surface receptor signaling pathway via JAK-STAT	1	290.6×	0.006	IFNAR2
cellular response to virus	1	200.6×	0.007	IFNAR2
response to virus	1	144.0×	0.009	IFNAR2
defense response to virus	1	69.3×	0.016	IFNAR2
cell surface receptor signaling pathway	1	64.1×	0.016	IFNAR2

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
IFNAR2	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	1	IFNAR2
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
IFNAR2	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 0.